Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
43.21
+5.40 (14.28%)
At close: Feb 20, 2026, 4:00 PM EST
43.34
+0.13 (0.30%)
After-hours: Feb 20, 2026, 7:40 PM EST
Spyre Therapeutics Employees
Spyre Therapeutics had 95 employees as of September 30, 2025. The number of employees increased by 35 or 58.33% compared to the same quarter last year.
Employees
95
Change
35
Growth
58.33%
Revenue / Employee
n/a
Profits / Employee
-$1,332,021
Market Cap
3.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | 101 | 11 | 12.22% |
| Sep 30, 2021 | 90 | 3 | 3.45% |
| Jun 30, 2021 | 91 | 8 | 9.64% |
| Mar 31, 2021 | 88 | 9 | 11.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Corcept Therapeutics | 500 |
| TG Therapeutics | 374 |
| Alumis | 223 |
| Arcellx | 163 |
| Centessa Pharmaceuticals | 114 |
| Erasca | 103 |
SYRE News
- 3 days ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 5 weeks ago - Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - GlobeNewsWire
- 7 weeks ago - Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
- 3 months ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 4 months ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 4 months ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - GlobeNewsWire